Key result
Carvedilol significantly reduced total body (-1.7 nmol/min) and cardiac norepinephrine spillover compared to metoprolol in patients with chronic heart failure (P<0.05).
Why the study?
Does carvedilol reduce systemic and cardiac norepinephrine spillover compared to metoprolol in patients with chronic heart failure?
Population
36 patients with chronic heart failure
Comparison
Carvedilol for 4 months vs Metoprolol (selective beta-blocker) for 4 months
Design
RCT, randomized, double-blind
Follow-up
4 months
Authors
Loading...
Carvedilol may be preferred over metoprolol in chronic heart failure for greater sympathoinhibition; extends mechanistic distinctions between beta-blockers.
RCT (n=36)
Double-blind
Does carvedilol reduce systemic and cardiac norepinephrine spillover compared to metoprolol in patients with chronic heart failure?
p-value: p=<0.05
Carvedilol, but not metoprolol, significantly decreases systemic and cardiac norepinephrine spillover in patients with chronic heart failure, suggesting a sympathoinhibitory effect via peripheral prejunctional beta-adrenergic receptor blockade.
Azevêdo et al. (2001) conducted an RCT in Chronic heart failure (n=36). Carvedilol vs. Metoprolol was evaluated on Total body and cardiac norepinephrine spillover (p=<0.05). Carvedilol significantly reduced total body (-1.7 nmol/min) and cardiac norepinephrine spillover compared to metoprolol in patients with chronic heart failure (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: